The National Center for Health Research analyzes and explains the latest research-based information that patients, policy makers, and the public can use to improve their own health and to develop better health programs and policies. The U.S. has the most expensive healthcare in the world, but we don’t live as long as men and women in Europe, Australia, or Canada.
To read more about us, check for job openings and more, click here.
In The NewsWith overactive bladder, drug companies helped create $3 billion market – MedPage Today & Milwaukee Journal Sentinel, October 15, 2016 – Diana Zuckerman, president of the National Center for Health Research noted there is another factor arguing against the use of drugs to treat overactive bladder. “All of these drugs have the potential for serious risk,” she said. “So what’s the actual benefit? To weigh that against risks that can be serious, it’s pretty unimpressive.” Continue readingAnthem says will not cover Sarepta’s approved Duchenne drug – Reuters, October 7, 2016 – To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said. Continue readingStatement of Dr. Diana Zuckerman, President, National Center for Health Research – Regarding Anthem Decision that Exondys 51 is Experimental – October 7, 2016 – We continue to strongly urge Sarepta to do the studies needed to support their claims that patients benefit from Exondys 51, and in the meanwhile Sarepta should ensure that patients in those studies receive the treatment for free. Continue readingAnthem declines to cover Sarepta drug for Duchenne, citing doubts over data – STAT News, October 7, 2016 – One of the nation’s largest health insurers has decided not to cover a controversial Duchenne muscular dystrophy drug because its FDA approval was not based on scientific evidence that it works. This is what NCHR predicted would happen. Continue readingDoes the FDA have a high enough standard for drug approvals? – STAT News, September 28, 2016 – Is the Food and Drug Administration’s approval process broken? At a HUBweek panel hosted by STAT, experts explored that question in light of the FDA’s decision last week to approve a controversial drug for Duchenne muscular dystrophy, a rare disease. Continue reading
Thanks to everyone who participated in our Introductory Patient Training Workshop on October 14-15, 2016, in Washington, D.C! If you’re interested in future workshops, check out our website: www.usapatientnetwork.org
Sign On To Our Letter To Congress
Congress is working on a law that would lower the standards for new medical products. Congress says it will benefit patients, but to be a “cure” a treatment should actually help patients, not just enrich stockholders.
What You Need To Know
Do you think drug ads are providing helpful information or selling us a fantasy about miracle cures?
See our 2015 survey results about problems with Essure permanent birth control.
Find out about our #LetterstoAnnie project. What killed Annie, a healthy young woman? How can you protect yourself or your daughter? Each week, we will unravel the mystery through letters from Annie’s mom to her daughter: www.letterstoannie.org
If you or a loved one have been harmed by a birth control pill or implant, click here.
Patient advocates from across the country joined us for a day of training to learn more about the FDA process and how patients can have their voices heard.
25 major medical groups recommended which medical tests you DON’T need. Why pay for tests that might even hurt you?
YAZ, Yasmin, Beyaz, and other drospirenone hormonal birth control pills have been found to put women at an increased risk for serious blood clots. Read why. Or read about all your birth control options.